Benefit of AI-assisted organ-at-risk contouring in head-and-neck cancer: A global randomized study

被引：0

作者：

Rasmussen, M. E. ^{[1
]}

Akbarov, K. ^{[2
]}

Titowich, E. ^{[2
]}

Wakeham, K. ^{[2
]}

Nijkamp, J. A. ^{[1
]}

Van Elmpt, W. ^{[3
]}

Mohamed, A. K. U. Ahmed ^{[4
]}

Erida, B. P. Brohet Kartika ^{[4
]}

Lomidze, C. N. Darejan ^{[4
]}

Ferraris, G. P. Gustavo ^{[4
]}

Stojkovski, H. M. Igor ^{[4
]}

Mohamad, I. I. Issa ^{[4
]}

Kochbati, L. S. Lotfi ^{[4
]}

Piatkevich, L. E. Maksim ^{[4
]}

Spahiu, M. M. B. J. Orges ^{[4
]}

Zakirova, R. A. Raushan ^{[4
]}

Tsegmed, S. S. S. K. Uranchimeg ^{[4
]}

Korreman, S. S. ^{[1
]}

Eriksen, J. G. ^{[1
]}

机构：

[1] ELAISA Consortium, Aarhus, Denmark

[2] ELAISA Consortium, lnternat Atom Energy Agcy, Vienna, Austria

[3] ELAISA Consortium, Maastricht, Netherlands

[4] ELAISA Consortium, Vienna, Austria

来源：

RADIOTHERAPY AND ONCOLOGY | 2023年 / 182卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OC-0828

引用

页码：S698 / S700

页数：3

共 39 条

[31] A prospective study of weekly intensity modulated radiation therapy plan adaptation for head and neck cancer: improved target coverage and organ at risk sparing
F. Aly
A. A. Miller
M. G. Jameson
P. E. Metcalfe
Australasian Physical & Engineering Sciences in Medicine, 2019, 42 : 43 - 51
[32] Acute mucosal reactions in continuous 7-day-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: evaluation of the data from a randomized clinical trial
Suwinski, R
Bankowska-Wozniak, M
Majewski, W
Sowa, A
Galwas, K
Miszczyk, L
Skladowski, K
Windorbska, W
Ziolkowska, E
Maciejewski, B
RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S80 - S80
[33] Activity of Temsirolimus Added to Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head-and-Neck Cancer: Results of the Randomized Phase 2 Maestro-HN Study Molecular Biology and Therapeutics
Seiwert, T. Y.
Adkins, D.
Worden, F.
Wade, J. L.
Hu, S.
Price, K.
Zavala, J.
Lussier, Y.
Vokes, E. E.
Cohen, E. E. W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 510 - 510
[34] Dosimetric, Radiobiological and Secondary Cancer Risk Evaluation in Head-and-Neck Three-dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, and Volumetric Modulated Arc Therapy: A Phantom Study
Rehman, Jalil Ur
Isa, Muhammad
Ahmad, Nisar
Nasar, Gulfam
Asghar, H. M. Noor Ul Huda Khan
Gilani, Zaheer Abbas
Chow, James C. L.
Afzal, Muhammad
Ibbott, Geoffrey S.
JOURNAL OF MEDICAL PHYSICS, 2018, 43 (02) : 129 - 135
[35] Erratum: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy. Results of a multicentric randomized German trial in advanced head-and-neck cancer (International Journal of Radiation Oncology Biology Physics 2001; 50: (1161-1171))
Staar, S.
Rudat, V.
Stuetzer, H.
Dietz, A.
Volling, P.
Schroeder, M.
Flentje, M.
Eckel, H.E.
Mueller, R.-P.
International Journal of Radiation Oncology Biology Physics, 2001, 51 (02):
[36] LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.
Burtness, Barbara
Bourhis, Jean
Vermorken, Jan Baptist
Dai, Luyan
Lind, Charlotte
Ehrnrooth, Eva
Cohen, Ezra E. W.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[37] Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Burtness, Barbara
Bourhis, Jean P.
Vermorken, Jan B.
Harrington, Kevin J.
Cohen, Ezra E. W.
TRIALS, 2014, 15
[38] Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
Barbara Burtness
Jean P Bourhis
Jan B Vermorken
Kevin J Harrington
Ezra EW Cohen
Trials, 15
[39] A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN).
Clump, David Anthony
Zandberg, Dan Paul
Skinner, Heath Devin
Ohr, James
Fenton, Moon Jung
Normolle, Daniel Paul
Beitler, Jonathan Jay
Bauman, Julie E.
Ferris, Robert L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 →